Evotec seen up on 2 bln euro buyout offer from Halozyme

Halozyme Therapeutics

15/11/2024 06:43

** German drug development company Evotec  EVTG.DE  are seen
up around 20% in Lang&Schwarz premarket indications after
biotech company Halozyme  HALO.O  made a 2 billion euro($2.11
billion) buyout offer to the company
    ** It said it intends to buy all shares of Evotec at 11
euros per share, which corresponds to a premium of 27.5% as per
Thursday closing price
    ** On Monday Evotec rose on the news of private investment
firm Triton buying over 9% stake in the company and considering
a potential buyout
    ** The news on Halozyme might spark a takeover battle, a
local trader said
    ** Evotec said in a statement it will analyze the expression
of interest from Halozyme and decide on next steps

($1 = 0.9493 euros)

 (Reporting by Isabel Demetz)
 ((Isabel.demetz@thomsonreuters.com))